MiMedx to Acquire Sanara MedTech, Expanding Wound Care Portfolio
MDXG sits 38% above its 52-week low of $3.025.
Summary
MiMedx is acquiring Sanara MedTech, a strategic move that broadens its advanced wound care and surgical offerings. The deal comes as MiMedx navigates a 33% Q1 sales decline and a net loss following Medicare reimbursement changes, though Q2 sales fell less than expected. This acquisition could provide a new growth avenue and diversify revenue away from the challenged core business. MiMedx will pay $33.00 cash and 0.4735 shares per Sanara share, valuing the stock portion at $2.00 per share. The deal includes a $300M Hayfin term loan and a $22.5M Sanara termination fee. The transaction signals a pivot toward M&A to offset organic headwinds, with MiMedx's market cap at $630M.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — MiMedx will pay $33.00 cash and 0.4735 shares per Sanara share, valuing the stock portion at $2.00 per share. The deal includes a $300M Hayfin term loan and a $22.5M Sanara termination fee.
At the time of this announcement, MDXG was trading at $4.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $630M. The 52-week trading range was $3.03 to $7.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.